BioReliance
 
Home About Us Services What's Your Product? Resources Careers Contact Us
  Home
 

News

David A. Dodd to Lead BioReliance Corporation
David A. Dodd has joined BioReliance as the Company's President, Chief Executive Officer and Chairman of the Board, effective December 3, 2007. From 2000 through 2006, Mr. Dodd served as President and CEO of Serologicals Corporation, a publicly traded company that was sold to Millipore Corporation in 2006 for $1.4 billion. Prior to that, from 1995 Mr. Dodd was President and CEO of Solvay Pharmaceuticals, Inc.
Click here to read the press release.
David L. Bellitt joins Bioreliance David L. Bellitt has been named Vice President of Global Commercial Operations, Biologics. Mr. Bellitt will be responsible for all global commercialization activities, including sales, marketing and customer service. He will also serve as a member of the Corporate Operating Committee.
Click here to read the press release.
BioReliance Corporation Launches iNet™ for Online Results Tracking of Biological Safety Tests BioReliance is pleased to announce to US customers the release of iNet, a proprietary information technology system for submitting and tracking test article details via a controlled and secure Internet access from any location worldwide. Now you can view the status of current and past studies, keep informed of when testing will be completed, download reports, and allow your colleagues to view the status of your tests.
Click here to read the press release.

 

     This page provides access to regulatory guidance and other resources that are generally available from web sites operated and maintained by other organisation.

World Health Organization (WHO)

The WHO Biologicals Quality Assurance and Safety web site provides WHO regulatory and technical guidance, norms and standards on the production and control of biological medicines and related in vitro diagnostic tests.

DOCUMENT TITLE*
*Note: these links take you directly to the documents on the WHO web site.  Please let us (info@bioreliance.com) know if you have problems accessing them.		 DOCUMENT TYPE DATE POSTED
on this website
Recommendations for the Production and Quality Control of Inactivated Influenza Vaccine (inactivated)
Further information 		WHO Recommendations February 2005

Requirements for the Use of Animal Cells as in vitro Substrates for the Production of Biologicals
Further information

WHO Recommendations February 2005

IMPORTANT NOTICE
The links on this page are provided for the sole purpose of assisting visitors to locate the relevant web sites and BioReliance does not make any warranty with respect to the accuracy of the documents available from these sites.  All documents are the copyright of the respective site owners and may be subject to certain conditions of use. Although care has been taken in the preparation of this web site BioReliance cannot be held responsible for the accuracy of the information contained within the web site, nor for any consequence arising from such information. You are advised to seek additional advice when making decisions based on information you have obtained from this web site.

  
for further information and enquiries please contact: info@bioreliance.com